← All Companies
AbbVie Inc.
ABBV · NYSE · SIC 2834: Pharmaceutical Preparations · Market Cap: $365.6B · 57,000 employees
Business Summary AbbVie Inc. is a global, diversified research-based biopharmaceutical company focused on immunology, neuroscience, oncology, and aesthetics. Key products include Skyrizi (risankizumab) and Rinvoq (upadacitinib) for autoimmune diseases, Humira (adalimumab), Vraylar (cariprazine) for neurological conditions, Imbruvica (ibrutinib) and Venclexta (venetoclax) for blood cancers, and Botox Cosmetic and Botox Therapeutic for aesthetic and therapeutic applications. AbbVie develops, manufactures, and commercializes therapies addressing complex and serious diseases globally.
Latest Stock Quote
ABBV 2026-04-10
$207.94
O:$213.55 H:$214.1 L:$207.75 Vol:4.6M VWAP:$209.1295
origin leaf: 957971f292892526d36e57101e6041db0c9d1f3e5630609ea913c63cc7070486
Next Earnings Q2 FY2026 — expected 2026-09-14
Key Facts from Earnings Calls Type Subject Detail Quarter topic_mention ABBV discussed_in_filing Blockchain & Crypto topic_mention ABBV discussed_in_filing Healthcare & Bio topic_mention ABBV discussed_in_filing Blockchain & Crypto topic_mention ABBV discussed_in_filing Healthcare & Bio topic_mention ABBV discussed_in_filing Blockchain & Crypto topic_mention ABBV discussed_in_filing Healthcare & Bio topic_mention ABBV discussed_in_filing Blockchain & Crypto topic_mention ABBV discussed_in_filing Healthcare & Bio
Annual Reports (10-K) Filed Period Accession Source Full Text 2026-02-20 2025-12-31 0001551152-26-000008 EDGAR 71K words 2025-02-14 2024-12-31 0001551152-25-000020 EDGAR — 2024-02-20 2023-12-31 0001551152-24-000011 EDGAR — 2023-02-17 2022-12-31 0001551152-23-000011 EDGAR — 2022-02-18 2021-12-31 0001551152-22-000007 EDGAR — 2021-02-19 2020-12-31 0001551152-21-000008 EDGAR — 2020-02-21 2019-12-31 0001551152-20-000007 EDGAR — 2019-02-27 2018-12-31 0001551152-19-000008 EDGAR — 2018-02-16 2017-12-31 0001551152-18-000014 EDGAR —
Quarterly Reports (10-Q) Filed Period Accession Source Full Text 2025-11-04 2025-09-30 0001551152-25-000049 EDGAR 26K words 2025-08-04 2025-06-30 0001551152-25-000040 EDGAR — 2025-05-09 2025-03-31 0001551152-25-000029 EDGAR — 2024-11-04 2024-09-30 0001551152-24-000040 EDGAR — 2024-08-07 2024-06-30 0001551152-24-000031 EDGAR — 2024-05-03 2024-03-31 0001551152-24-000020 EDGAR — 2023-11-06 2023-09-30 0001551152-23-000045 EDGAR — 2023-08-07 2023-06-30 0001551152-23-000033 EDGAR — 2023-05-05 2023-03-31 0001551152-23-000023 EDGAR — 2022-11-04 2022-09-30 0001551152-22-000045 EDGAR — 2022-08-04 2022-06-30 0001551152-22-000030 EDGAR — 2022-05-06 2022-03-31 0001551152-22-000017 EDGAR —
Recent Current Reports (8-K) Filed Accession Source Full Text 2026-04-03 0001551152-26-000011 EDGAR 1K words 2026-03-04 0001104659-26-023534 EDGAR — 2026-02-26 0001104659-26-020643 EDGAR — 2026-02-04 0001551152-26-000004 EDGAR — 2026-01-07 0001551152-26-000002 EDGAR — 2025-10-31 0001551152-25-000047 EDGAR — 2025-10-03 0001551152-25-000043 EDGAR — 2025-09-11 0001104659-25-089245 EDGAR — 2025-07-31 0001551152-25-000036 EDGAR — 2025-07-03 0001551152-25-000034 EDGAR —
192 total filings indexed. 161 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
Sector Peers Tags immunology neuroscience oncology aesthetics rheumatology dermatology gastroenterology hematology
Company Identity
CIK 0001551152
Ticker ABBV
Exchange NYSE
SIC 2834: Pharmaceutical Preparations
Incorporated DE
Website https://www.abbvie.com
Listed 2012-12-10
Get More Data
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile
Stock Quote
AI Readiness Report
Origin Provenance
page leaf: 779787f64becdca9270ffed9cfcaebc51d5f3ccaead632968ecd7a80bb19ab72
parent: aeff3ad84fa45b87d3d1bec8f3b47d5fa6a567e652b92846fdd346502107ae73
content hash: de7169d3df489a2dd9485939b460d407880d6c42d0b385517112faed5c27fa6d
signed: 2026-04-13T04:43:24.789Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf